Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash & Equivalents (2020 - 2023)

Terns Pharmaceuticals' Cash & Equivalents history spans 4 years, with the latest figure at $37.9 million for Q3 2023.

  • For Q3 2023, Cash & Equivalents fell 39.83% year-over-year to $37.9 million; the TTM value through Sep 2023 reached $37.9 million, down 39.83%, while the annual FY2022 figure was $143.2 million, 200.29% up from the prior year.
  • Cash & Equivalents reached $37.9 million in Q3 2023 per TERN's latest filing, down from $80.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $169.4 million in Q1 2023 to a low of $11.7 million in Q1 2020.
  • Average Cash & Equivalents over 4 years is $63.6 million, with a median of $63.0 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: surged 744.98% in 2021, then crashed 75.14% in 2022.
  • A 4-year view of Cash & Equivalents shows it stood at $74.9 million in 2020, then crashed by 36.28% to $47.7 million in 2021, then soared by 200.29% to $143.2 million in 2022, then plummeted by 73.54% to $37.9 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Cash & Equivalents are $37.9 million (Q3 2023), $80.9 million (Q2 2023), and $169.4 million (Q1 2023).